Table 2.
Net-League Estimates of MACE Over 1 and 5 Year Across Different Treatment Strategies Showing Risk Ratio With Its 95% CI
| 1-Year MACE | |||||||||||
| BMS | 1.60 (1.41-1.81) | 1.77 (1.49-2.12) | 1.46 (1.01-2.10) | 1.84 (1.63-2.07) | 1.48 (0.99-2.21) | 1.68 (1.39-2.02) | 1.90 (1.50-2.41) | 1.78 (1.60-1.97) | 1.26 (1.13-1.41) | 1.70 (1.53-1.89) | 1.66 (1.49-1.85) |
| 1.34 (1.21-1.50) | PA-BES | 1.11 (0.94-1.31) | 0.91 (0.62-1.34) | 1.15 (1.02-1.29) | 0.93 (0.62-1.38) | 1.05 (0.87-1.27) | 1.19 (0.94-1.51) | 1.11 (1.01-1.23) | 0.79 (0.70-0.89) | 1.06 (0.95-1.19) | 1.03 (0.92-1.16) |
| 1.39 (1.14-1.69) | 1.03 (0.85-1.25) | PA-EES | 0.82 (0.55-1.23) | 1.04 (0.87-1.23) | 0.84 (0.55-1.27) | 0.95 (0.75-1.19) | 1.07 (0.82-1.41) | 1.00 (0.85-1.18) | 0.71 (0.59-0.85) | 0.96 (0.80-1.14) | 0.93 (0.78-1.11) |
| 1.51 (0.86-2.65) | 1.12 (0.63-1.99) | 1.09 (0.60-1.97) | PA-PES | 1.26 (0.86-1.85) | 1.02 (0.59-1.75) | 1.15 (0.76-1.74) | 1.31 (0.84-2.02) | 1.22 (0.83-1.78) | 0.87 (0.59-1.27) | 1.17 (0.80-1.71) | 1.14 (0.78-1.66) |
| 1.42 (1.25-1.61) | 1.05 (0.94-1.18) | 1.02 (0.84-1.24) | 0.94 (0.53-1.67) | PA-SES | 0.81 (0.54-1.20) | 0.91 (0.76-1.10) | 1.04 (0.82-1.31) | 0.97 (0.89-1.05) | 0.69 (0.61-0.78) | 0.93 (0.83-1.04) | 0.90 (0.81-1.00) |
| 1.64 (0.99-2.73) | 1.22 (0.73-2.04) | 1.18 (0.69-2.02) | 1.09 (0.51-2.32) | 1.16 (0.69-1.94) | PF-AES | 1.13 (0.75-1.72) | 1.28 (0.82-2.00) | 1.20 (0.81-1.78) | 0.85 (0.57-1.27) | 1.15 (0.77-1.71) | 1.12 (0.76-1.65) |
| 1.45 (1.22-1.71) | 1.08 (0.92-1.27) | 1.04 (0.83-1.31) | 0.96 (0.53-1.73) | 1.02 (0.86-1.21) | 0.88 (0.52-1.49) | PF-SES + Probucol | 1.13 (0.86-1.49) | 1.06 (0.89-1.26) | 0.75 (0.62-0.91) | 1.01 (0.84-1.22) | 0.99 (0.85-1.15) |
| 1.89 (1.47-2.43) | 1.40 (1.09-1.81) | 1.36 (1.01-1.83) | 1.25 (0.68-2.32) | 1.33 (1.03-1.72) | 1.15 (0.66-2.01) | 1.30 (1.00-1.70) | PF-TiNO | 0.93 (0.75-1.17) | 0.66 (0.52-0.84) | 0.89 (0.71-1.13) | 0.87 (0.69-1.09) |
| 1.44 (1.31-1.59) | 1.07 (0.99-1.17) | 1.04 (0.87-1.24) | 0.96 (0.54-1.69) | 1.02 (0.93-1.12) | 0.88 (0.53-1.46) | 1.00 (0.86-1.15) | 0.76 (0.60-0.97) | PP-EES | 0.71 (0.64-0.78) | 0.96 (0.87-1.05) | 0.93 (0.85-1.02) |
| 1.17 (1.06-1.29) | 0.87 (0.78-0.97) | 0.84 (0.69-1.02) | 0.77 (0.44-1.37) | 0.82 (0.73-0.93) | 0.71 (0.43-1.17) | 0.81 (0.69-0.94) | 0.62 (0.48-0.79) | 0.81 (0.74-0.88) | PP-PES | 1.35 (1.21-1.50) | 1.31 (1.18-1.46) |
| 1.28 (1.16-1.41) | 0.95 (0.88-1.03) | 0.92 (0.76-1.12) | 0.85 (0.48-1.50) | 0.90 (0.81-1.00) | 0.78 (0.47-1.30) | 0.88 (0.75-1.04) | 0.68 (0.53-0.87) | 0.89 (0.82-0.96) | 1.10 (1.00-1.21) | PP-SES | 0.97 (0.88-1.08) |
| 1.44 (1.28-1.64) | 1.07 (0.96-1.21) | 1.04 (0.86-1.26) | 0.96 (0.54-1.70) | 1.02 (0.90-1.16) | 0.88 (0.53-1.47) | 1.00 (0.89-1.12) | 0.76 (0.60-0.97) | 1.00 (0.92-1.10) | 1.24 (1.11-1.38) | 1.13 (1.01-1.26) | PP-ZES |
| 5-Year MACE | |||||||||||
AES = amphilimus-eluting stent; MACE = major adverse cardiovascular events; PF = polymer free; TiNO = titanium-nitride-oxide; other abbreviations as in Table 1.